{"gene":"EEF1A2","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1998,"finding":"The lethal wasted (wst) mouse phenotype is caused by a 15.8 kb deletion that abolishes expression of Eef1a2, a tissue-specific translation elongation factor. eEF1A2 expression is reciprocal with eEF1A1 in heart and muscle postnatally, establishing that tissue-specific isoforms of the translation elongation apparatus are essential for postnatal survival.","method":"Genetic deletion mapping, Northern blot expression analysis, in vivo mouse genetics","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — precise genetic deletion identified, reciprocal expression pattern established, causal link confirmed by transgenic rescue experiments in subsequent work; independently replicated across multiple labs","pmids":["9539760"],"is_preprint":false},{"year":2007,"finding":"Transgenic rescue experiments established that loss of eEF1A2 function alone is responsible for all abnormalities in wasted mice, including motor neuron degeneration. eEF1A2 is expressed at high levels in specific cell types including pancreatic islet cells and enteroendocrine cells. Expression of eEF1A1 and eEF1A2 is mutually exclusive in individual cell types, and the motor neuron degeneration phenotype relates precisely to the relative expression of the two isoforms.","method":"Transgenic rescue, anti-peptide antibody immunohistochemistry, cell-type-specific expression analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — transgenic rescue is definitive functional test, multiple orthogonal methods, causal conclusion firmly established","pmids":["17640869"],"is_preprint":false},{"year":2002,"finding":"EEF1A2 has oncogenic properties: it enhances focus formation, allows anchorage-independent growth, decreases doubling time of rodent fibroblasts, and makes NIH3T3 fibroblasts tumorigenic in nude mice, establishing EEF1A2 as a functional oncogene.","method":"Focus formation assay, anchorage-independent growth assay, xenograft tumor model","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple functional oncogenicity assays in vitro and in vivo, independently replicated in subsequent studies","pmids":["12053177"],"is_preprint":false},{"year":2006,"finding":"eEF1A2 expression is sufficient to activate Akt in a PI3K-dependent manner, stimulate filopodia formation dependent on PI3K, ROCK, and Akt kinases, and promote cell migration and invasion in breast cancer cells. siRNA-mediated reduction of eEF1A2 reduces Akt activity.","method":"siRNA knockdown, Western blot for phospho-Akt, filopodia imaging, migration/invasion assays with kinase inhibitors","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function experiments with multiple pathway inhibitors and cellular readouts, single lab but multiple orthogonal methods","pmids":["17130842"],"is_preprint":false},{"year":2006,"finding":"eEF1A2 directly binds to and activates phosphatidylinositol 4-kinase IIIβ (PI4KIIIβ). Purified recombinant eEF1A2 increases PI4KIIIβ lipid kinase activity in vitro, and eEF1A2 expression in cells increases cellular PI4-kinase activity and intracellular phosphatidylinositol 4-phosphate abundance. siRNA knockdown of eEF1A2 concomitantly reduces PI4-kinase activity.","method":"In vitro lipid kinase assay with purified recombinant proteins, siRNA knockdown, cellular PI4P measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified proteins plus cellular gain/loss-of-function confirmation, single lab with multiple orthogonal methods","pmids":["17088255"],"is_preprint":false},{"year":2007,"finding":"Mouse eEF1A2 interacts with peroxiredoxin I (Prdx-I) but not with its isoform eEF1A1. The eEF1A2–Prdx-I complex confers resistance to peroxide-induced cell death, reducing activation of caspases 3 and 8 and increasing Akt expression. This interaction is isoform-specific.","method":"Yeast two-hybrid screening, co-immunoprecipitation from cells and mouse tissues, double transfectant cell death assays, caspase activation assays","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP from multiple sources confirms interaction; isoform specificity validated; functional consequence shown in cells; single lab","pmids":["16888816"],"is_preprint":false},{"year":2014,"finding":"EEF1A2 acts as an upstream inducer of PI3K to support MDM4 stabilization in hepatocellular carcinoma. The EEF1A2/PI3K/AKT/mTOR axis promotes protumorigenic stabilization of MDM4 via post-transcriptional mechanism, inactivating p53. EEF1A2, phosphorylated AKT, and MDM4 expression are strongly correlated (each rho >0.8) in human HCC.","method":"Silencing and overexpression experiments in HCC cell lines, PI3K/AKT/mTOR pathway inhibition, Western blot, in vivo AKT mouse model, human HCC tissue correlation analysis","journal":"Hepatology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway placement by epistasis with multiple inhibitors, in vivo model, human tissue validation; single lab, pathway mechanism partially inferred","pmids":["24285179"],"is_preprint":false},{"year":2010,"finding":"eEF1A2 binds the 5'-UTR of utrophin A mRNA and promotes IRES-dependent (cap-independent) translation specifically in skeletal muscle. RNA-affinity chromatography identified eEF1A2 as a trans-factor binding the utrophin A 5'-UTR; UV-crosslinking confirmed specificity. Cells lacking eEF1A2 had reduced IRES activity, while eEF1A2 overexpression increased it.","method":"RNA-affinity chromatography combined with mass spectrometry, UV-crosslinking, IRES reporter assays in cultured cells, transgenic mice","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — biochemical identification plus functional IRES assay and in vivo transgenic confirmation; multiple orthogonal methods in one study","pmids":["20053670"],"is_preprint":false},{"year":2016,"finding":"eEF1A2 is the primary anticancer target of plitidepsin. The drug interacts with eEF1A2 with a KD of 80 nM. Tumor cell lines selected for ≥100-fold plitidepsin resistance show reduced eEF1A2 protein levels; ectopic eEF1A2 expression in resistant cells restores plitidepsin sensitivity. FLIM-phasor FRET experiments demonstrate drug-protein complex formation in living cells. Molecular modelling identifies a binding site at the interface of domains 1 and 2 of eEF1A2 in the GTP conformation.","method":"Binding affinity measurements, [14C]-plitidepsin cell lysate pull-down, resistance selection, ectopic expression rescue, FLIM-phasor FRET in living cells, molecular modelling","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical and cellular methods including direct binding measurement, genetic rescue, and live-cell FRET; robust mechanistic evidence","pmids":["27713531"],"is_preprint":false},{"year":2013,"finding":"Tumor suppressor p16(INK4a) directly interacts with eEF1A2 (identified by yeast two-hybrid), binding all domains except D2 (250–327 aa). Ectopic p16(INK4a) expression decreases eEF1A2 expression and suppresses protein synthesis as measured by luciferase reporter activity. Microinjection of p16(INK4a) mRNA into Xenopus embryos suppressed luciferase mRNA translation, and combined p16(INK4a) plus morpholino-eEF1A2 further reduced translational activity.","method":"Yeast two-hybrid, domain mapping, luciferase reporter translation assay, Xenopus embryo microinjection with morpholino knockdown","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus functional translation assays in two model systems; interaction not confirmed by co-IP in mammalian cells; single lab","pmids":["23444377"],"is_preprint":false},{"year":2018,"finding":"eEF1A2 binds to double-stranded RNA-activated protein kinase (PKR), inhibiting its pro-apoptotic kinase activity likely through sequestration. Targeting eEF1A2 with plitidepsin releases PKR from the complex, facilitating PKR activation, triggering MAPK signaling and NF-κB-dependent extrinsic apoptosis, leading to tumor cell death.","method":"Co-immunoprecipitation, HPLC-mass spectrometry, proximity ligation assay, plitidepsin displacement experiments, cell death assays","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP plus proximity ligation assay confirm interaction; functional consequence shown by chemical displacement; single lab","pmids":["30420615"],"is_preprint":false},{"year":2021,"finding":"Phosphorylation of isoform-specific sites in eEF1A2 coordinates translation and actin dynamics in dendritic spines. A nonphosphorylatable eEF1A2 mutant stimulates mRNA translation but reduces actin dynamics and spine density. A phosphomimetic mutant exhibits decreased F-actin association and is inactive as a translation elongation factor. Metabotropic glutamate receptor signaling triggers transient phosphorylation-dependent dissociation of eEF1A2 from its guanine exchange factor in dendritic spines.","method":"Phosphomutant/phosphomimetic expression, translation assays, actin dynamics imaging, dendritic spine density quantification, mGluR signaling experiments with co-localization","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple mutant constructs with orthogonal readouts (translation, actin, spine morphology, GEF interaction), mechanistic model experimentally validated","pmids":["34257105"],"is_preprint":false},{"year":2023,"finding":"Three patient-associated EEF1A2 mutations (G70S, E122K, D252H) decrease de novo protein synthesis and elongation rates in HEK293 cells. In mouse cortical neurons these mutations decrease protein synthesis and alter neuronal morphology independently of endogenous eEF1A2 levels, indicating toxic gain-of-function. Mutant eEF1A2 proteins display increased tRNA binding and decreased actin-bundling activity, suggesting dual disruption of tRNA availability and actin cytoskeleton.","method":"Heterologous expression in HEK293 cells and mouse cortical neurons, puromycin incorporation (de novo synthesis assay), elongation rate measurement, tRNA binding assay, actin-bundling assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple patient mutations tested with in vitro biochemical assays (tRNA binding, actin bundling) plus cellular translation assays; mechanistic conclusions supported by multiple orthogonal methods","pmids":["37695913"],"is_preprint":false},{"year":2009,"finding":"Three-dimensional homology models of eEF1A1 and eEF1A2 based on yeast eEF1A crystal structure reveal that nearly all variant surface-exposed residues lie in two proximal but distinct sub-clusters on one face of the protein. No buried residue differences are predicted to affect protein fold or domain-domain interactions. Predicted variant-specific phosphorylation sites may explain functional differences between the two isoforms.","method":"Comparative 3D homology modelling validated against yeast crystal structure, surface electrostatic and lipophilic property analysis, sequence-based phosphorylation prediction","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — structural modelling with validation but no mutagenesis or direct experimental confirmation of predicted sites; predictions provide testable hypotheses","pmids":["19636410"],"is_preprint":false},{"year":2013,"finding":"eEF1A2 promotes cell migration, invasion, and peritoneal metastasis in pancreatic cancer through upregulation of MMP-9 expression and activity. This effect is dependent on eEF1A2-induced Akt activation; inhibition of MMP-9 activity or Akt reduces the promoting effect of eEF1A2 on cell migration and invasion.","method":"siRNA knockdown, ectopic overexpression, migration/invasion assays, MMP-9 activity assay (gelatin zymography), Akt inhibition, in vivo peritoneal metastasis mouse model","journal":"Clinical & experimental metastasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function with multiple downstream readouts and pathway inhibition; single lab","pmids":["23739844"],"is_preprint":false},{"year":2010,"finding":"shRNA-mediated knockdown of Eef1a2 in mouse plasmacytomas causes growth inhibition from delayed G1-S progression and apoptosis under serum-starved conditions. Transcriptional profiling and Western blot reveal impaired JAK/STAT and PI3K/AKT signaling as downstream consequences of Eef1a2 knockdown.","method":"shRNA knockdown, flow cytometry cell cycle analysis, apoptosis assay, transcriptional profiling, Western blot for JAK/STAT and PI3K/AKT pathway components","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean knockdown with defined cell cycle and pathway readouts; single lab, no rescue experiment","pmids":["20505761"],"is_preprint":false},{"year":2021,"finding":"EEF1A2 interacts with HSP90AB1 (Hsp90β) to increase TGF-β receptor I and II expression, enhancing SMAD3 phosphorylation and nuclear localization, thereby promoting epithelial-mesenchymal transition and metastasis of lung adenocarcinoma cells.","method":"LC-MS/MS proteomics identification of binding partners, co-immunoprecipitation, immunofluorescence co-localization, in vitro and in vivo metastasis assays, Western blot for TGF-β signaling components","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding partner identified by mass spectrometry and confirmed by reciprocal co-IP; pathway downstream effects demonstrated; single lab","pmids":["33473168"],"is_preprint":false},{"year":2020,"finding":"Heterozygous de novo EEF1A2 variants are functionally validated as protein-damaging using heterologous expression and complementation analysis in yeast. Pathogenic variants disrupt both the protein synthesis and integrated stress response functions of eEF1A2, and appear to act via haploinsufficiency.","method":"Heterologous expression, yeast complementation assay, functional translation assays","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro/yeast functional validation of multiple patient variants with complementation; single study, mechanism partially inferred","pmids":["32196822"],"is_preprint":false},{"year":2017,"finding":"In zebrafish, eef1a2 deficiency (morpholino knockdown) causes skeletal muscle weakness, cardiac failure, and small heads. Human wild-type EEF1A2 mRNA rescues the morphant phenotype, but the pathogenic p.P333L mutant RNA does not, confirming that the mutation impairs eEF1A2 function. In yeast, previously identified de novo mutations fail to complement eEF1A ortholog deletion (growth defect), while p.P333L causes a milder growth defect without dominant-negative effect.","method":"Zebrafish morpholino knockdown, mRNA rescue experiment, yeast complementation assay","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — two independent model systems (zebrafish and yeast) with rescue experiments; wild-type vs. mutant mRNA discrimination establishes functional deficit","pmids":["28911200"],"is_preprint":false},{"year":2017,"finding":"eEF1A1 (but not eEF1A2) binds calmodulin, which interferes with eEF1A1's tRNA-binding and actin-bundling activities in vitro. Both isoforms exhibit actin-bundling activity but form morphologically distinct bundle types. eEF1A2 cannot be controlled by Ca2+-mediated regulatory systems through calmodulin.","method":"In vitro binding assays, actin-bundling assay, tRNA-binding assay, calmodulin pull-down","journal":"Biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro biochemical assays comparing both isoforms; single lab; no cellular validation of calmodulin-independence","pmids":["27483363"],"is_preprint":false},{"year":2014,"finding":"The eEF1B complex subunits (eEF1Bα, eEF1Bδ, eEF1Bγ) co-localize with both eEF1A1 and eEF1A2 in sufficiently close proximity to suggest complex formation. Ablation of any eEF1B subunit in human cell lines has a small but significant impact on cell viability and cycling.","method":"Co-localization immunofluorescence/proximity assay, siRNA knockdown of eEF1B subunits, cell viability and cell cycle assays","journal":"PloS one","confidence":"Low","confidence_rationale":"Tier 3 / Weak — co-localization supports but does not definitively prove physical interaction of eEF1A2 with eEF1B; no biochemical pull-down for eEF1A2-eEF1B shown","pmids":["25436608"],"is_preprint":false},{"year":2020,"finding":"Transient overexpression of eEF1A2 in mouse muscles increases IRES-mediated translation of utrophin A. FDA-approved drugs that increase eEF1A2 protein levels also upregulate utrophin A, and treatment of mdx mice with two top lead compounds improves the dystrophic phenotype, establishing eEF1A2-driven IRES translation of utrophin A as a therapeutically relevant mechanism.","method":"Transient overexpression in mouse muscle, IRES reporter assay, ELISA-based high-throughput drug screen, mdx mouse treatment with phenotypic assessment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo overexpression with direct IRES reporter readout, confirmed in disease model; multiple orthogonal methods including drug screen and in vivo rescue","pmids":["32332749"],"is_preprint":false},{"year":2011,"finding":"eEF1A2 expression phenocopies PI4KIIIβ in disrupting three-dimensional mammary acinar morphogenesis. Both eEF1A2 and PI4KIIIβ alter intracellular localization of PI(4)P and PI(4,5)P2 within acini, indicating that eEF1A2-mediated PI4P generation is relevant to mammary neoplasia.","method":"3D acinar morphogenesis assay in MCF10A cells, PI(4)P and PI(4,5)P2 localization by immunofluorescence, ectopic expression of eEF1A2 and PI4KIIIβ","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cellular morphogenesis assay with lipid localization readout; consistent with known eEF1A2-PI4KIIIβ biochemical interaction; single lab","pmids":["21851817"],"is_preprint":false},{"year":2024,"finding":"KAT8 acts as a pan-lysine lactyltransferase (Kla writer) responsible for installing lactylation on eEF1A2 at K408. Lactylation of eEF1A2-K408 boosts translation elongation and enhances protein synthesis, contributing to colorectal carcinogenesis. Deletion of KAT8 inhibits CRC tumor growth, especially in a high-lactic tumor microenvironment.","method":"Global lactylation profiling in CRC, screening of eEF1A2-interacting proteins, KAT8 identification as lactyltransferase, site-specific lactylation at K408, in vitro and in vivo translation/tumor growth assays, KAT8 deletion experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-specific PTM identified with functional translation readout and in vivo tumor model; single lab, KAT8 mechanism partially characterized","pmids":["38359291"],"is_preprint":false},{"year":2022,"finding":"METTL14-mediated m6A modification of EEF1A2 mRNA decreases EEF1A2 expression. Silencing METTL14 inhibits m6A modification of EEF1A2, increases EEF1A2 protein levels, and activates the Akt/mTOR pathway to promote spinal cord neuron survival. Overexpression of EEF1A2 promotes neuron viability and inhibits apoptosis via Akt/mTOR activation.","method":"m6A methylation assay, METTL14 silencing/overexpression, EEF1A2 overexpression, Western blot for Akt/mTOR pathway, apoptosis and viability assays in rat SCI model","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — m6A writer identified with causal link to EEF1A2 expression and downstream pathway activation; single lab, pathway placement by epistasis","pmids":["35013140"],"is_preprint":false},{"year":2020,"finding":"SNX16 interacts with eEF1A2 and inhibits its ubiquitination and proteasomal degradation, leading to eEF1A2 protein stabilization and downstream activation of c-Myc signaling in colorectal cancer.","method":"Co-immunoprecipitation of SNX16-eEF1A2 complex, ubiquitination assay, proteasome inhibitor experiments, c-Myc pathway analysis by Western blot","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP confirms interaction, ubiquitination assay shows mechanistic regulation of eEF1A2 stability; single lab","pmids":["31876369"],"is_preprint":false},{"year":2023,"finding":"A20 interacts with eEF1A2 through its ZnF4 domain to ubiquitinate and degrade eEF1A2. Nrf2 transcriptionally regulates A20 expression by binding its promoter. This Nrf2/A20/eEF1A2 axis modulates NF-κB pathway activity and regulates pyroptosis in cerebral ischemia-reperfusion injury.","method":"Co-immunoprecipitation, dual-luciferase reporter assay, chromatin immunoprecipitation, gene overexpression/silencing experiments, Western blot","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus ChIP and luciferase assay define pathway; domain-level interaction mapped; single lab","pmids":["37399716"],"is_preprint":false},{"year":2023,"finding":"NSUN6 methylates EEF1A2 mRNA at m5C sites and increases mRNA stability in an m5C-dependent manner, thereby upregulating EEF1A2 expression and activating the Akt/mTOR signaling pathway in osteosarcoma.","method":"RNA immunoprecipitation (RIP), methylated RIP assay, NSUN6 knockdown/overexpression, mRNA stability assay, Western blot for Akt/mTOR pathway","journal":"Experimental and therapeutic medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — m5C writer identified with mRNA stability readout and downstream pathway; single lab","pmids":["37614424"],"is_preprint":false},{"year":2008,"finding":"Loss of eEF1A2 expression in motor neurons of wasted mice triggers dying-back neuropathy with synaptic loss at the neuromuscular junction preceding axonal pathology, morphologically distinct from Wallerian degeneration. Loss of eEF1A2 also significantly delays Wallerian degeneration after nerve lesion, and correlates with reduced ZPR1 expression.","method":"In vivo neuromuscular junction morphology analysis, tibial nerve lesion model, immunohistochemistry for eEF1A2 and ZPR1, comparison of wasted vs. wild-type mice","journal":"Journal of anatomy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined in vivo phenotype with mechanistic distinction between two degeneration pathways using genetic model; single lab","pmids":["19094180"],"is_preprint":false},{"year":2024,"finding":"SIMALR lncRNA binds eEF1A2 and enhances its endogenous GTPase activity. SIMALR further mediates activation of eEF1A2 phosphorylation to accelerate translation of ITGB4/ITGA6 mRNAs, promoting NPC malignant phenotype.","method":"RNA-binding assay (SIMALR-eEF1A2 interaction), GTPase activity assay, phosphorylation analysis, polysome profiling for target mRNA translation","journal":"Oncogene","confidence":"Low","confidence_rationale":"Tier 3 / Weak — abstract describes GTPase activity enhancement and phosphorylation promotion; mechanistic details of RNA-protein interaction and specific assay methods not fully described in abstract","pmids":["39154122"],"is_preprint":false},{"year":2023,"finding":"EEF1A2 acts as an RNA-binding protein/transcriptional co-factor that cooperates with circ-CDYL to initiate COL14A1 transcription in hepatocellular carcinoma cancer stem cells, promoting ERK signaling and EMT-driven lung metastasis.","method":"Mechanistic studies identifying EEF1A2 as transcriptional co-factor with circ-CDYL; COL14A1 transcription assay; ERK signaling pathway analysis","journal":"Cancer letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — non-canonical transcriptional co-factor role described for EEF1A2 but experimental details are sparse in abstract; single study","pmids":["37852428"],"is_preprint":false},{"year":2008,"finding":"ZNF217-induced neoplastic properties in ovarian surface epithelial cells are mediated through eEF1A2: siRNA targeting eEF1A2 efficiently inhibits both anchorage independence and resistance to apoptosis conferred by ZNF217 overexpression, placing eEF1A2 downstream of ZNF217 in this oncogenic pathway.","method":"Lentiviral overexpression, siRNA knockdown, anchorage-independent growth assay, apoptosis resistance assay, array CGH, SNP analysis","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by siRNA rescue of ZNF217 phenotype; multiple oncogenicity assays; single lab","pmids":["18661515"],"is_preprint":false},{"year":2020,"finding":"eEF1A2 knockdown in MPP+-treated dopaminergic cells decreases autophagy markers (LC3-II/LC3-I ratio, LC3 puncta, phospho-Beclin-1), reduces mitophagy, aggravates α-synuclein accumulation, and increases apoptosis, indicating eEF1A2 is required for autophagic flux and dopaminergic neuron survival under oxidative stress.","method":"eEF1A2 siRNA knockdown in differentiated SH-SY5Y cells with MPP+ treatment, LC3 immunofluorescence, mitochondrial membrane potential assay, caspase-3/7 activation assay","journal":"Neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean knockdown with multiple autophagy readouts; single lab, no rescue experiment","pmids":["32275913"],"is_preprint":false},{"year":2023,"finding":"EEF1A2 promotes HIF1A expression via ERK-Myc and mTOR signaling under normoxia, and hypoxia induces EEF1A2 expression; HIF1A binds the EEF1A2 promoter and induces its transcription, creating a positive feedback loop. EEF1A2 positively affects VEGF transcription and translation, increasing VEGF release to activate ERK and PI3K-AKT signaling in endothelial cells.","method":"Luciferase assay and EMSA confirming HIF1A binding to EEF1A2 promoter, RT-PCR, polysome profiling for VEGF translation, angiogenesis assays (CAM, tubulogenesis, aortic ring, Matrigel plug)","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — EMSA and luciferase assay provide direct evidence for HIF1A-eEF1A2 promoter binding; polysome profiling for translational regulation; multiple in vivo angiogenesis models; single lab","pmids":["38012382"],"is_preprint":false}],"current_model":"eEF1A2 is a tissue-specific translation elongation factor (restricted to neurons, cardiomyocytes, and muscle) that delivers aminoacyl-tRNAs to the ribosome A-site in a GTP-dependent manner; beyond canonical translation, it activates PI3K/AKT and JAK/STAT oncogenic signaling, directly binds and activates PI4KIIIβ to generate PI(4)P, interacts with peroxiredoxin I to confer oxidative stress resistance, sequesters and inhibits the pro-apoptotic kinase PKR, promotes IRES-dependent translation of utrophin A in muscle, coordinates actin dynamics and spine structural plasticity through phosphorylation-dependent dissociation from its GEF, and is subject to post-translational regulation including lactylation at K408 (installed by KAT8), m6A methylation (by METTL14), m5C methylation (by NSUN6), ubiquitination (regulated by SNX16 and A20), and phosphorylation at isoform-specific sites that toggle its activity between translation elongation and actin bundling."},"narrative":{"mechanistic_narrative":"EEF1A2 is a tissue-restricted isoform of the translation elongation factor eEF1A whose expression is reciprocal with eEF1A1 and is essential for postnatal survival of neurons and muscle, as established by the lethal motor neuron degeneration of the Eef1a2-null wasted mouse and its rescue by transgenic eEF1A2 [PMID:9539760, PMID:17640869, PMID:19094180]. In its canonical role it delivers aminoacyl-tRNAs during elongation, an activity directly demonstrated through tRNA-binding and de novo synthesis assays of patient mutants and through complementation of yeast eEF1A deletion [PMID:37695913, PMID:32196822, PMID:28911200]. Beyond bulk elongation, eEF1A2 binds the utrophin A 5'-UTR to drive cap-independent (IRES) translation specifically in skeletal muscle, a mechanism that can be pharmacologically exploited to improve the dystrophic phenotype of mdx mice [PMID:20053670, PMID:32332749]. eEF1A2 has a second, isoform-specific cytoskeletal function as an actin-bundling protein; in dendritic spines, phosphorylation of isoform-specific sites toggles it between an elongation-competent state and an actin-regulating state, with mGluR signaling triggering its dissociation from its guanine-exchange factor [PMID:34257105], and disease mutations simultaneously increase tRNA binding while reducing actin bundling [PMID:37695913]. eEF1A2 also functions as a potent oncogene: it transforms fibroblasts and confers anchorage-independent growth [PMID:12053177], and it activates PI3K/AKT signaling to promote migration, invasion and MMP-9-dependent metastasis, to stabilize MDM4 and inactivate p53, and to support JAK/STAT-dependent tumor cell survival [PMID:17130842, PMID:23739844, PMID:24285179, PMID:20505761]. Mechanistically it directly binds and activates PI4KIIIβ to generate PI(4)P [PMID:17088255, PMID:21851817], interacts with HSP90β to amplify TGF-β/SMAD3 signaling [PMID:33473168], sequesters and inhibits the pro-apoptotic kinase PKR [PMID:30420615], and participates in HIF1A/VEGF angiogenic feedback [PMID:38012382]. Its abundance and activity are heavily post-translationally controlled — by KAT8-installed K408 lactylation that boosts elongation [PMID:38359291], by METTL14 m6A and NSUN6 m5C marks on its mRNA [PMID:35013140, PMID:37614424], and by ubiquitin-dependent turnover regulated by SNX16 and A20 [PMID:31876369, PMID:37399716]. eEF1A2 is the molecular target of the anticancer drug plitidepsin, which binds the domain 1/2 interface in the GTP conformation and releases PKR to trigger apoptosis [PMID:27713531, PMID:30420615]. Heterozygous de novo EEF1A2 variants cause neurodevelopmental disease, acting through haploinsufficiency or toxic gain-of-function depending on the allele [PMID:32196822, PMID:37695913, PMID:28911200].","teleology":[{"year":1998,"claim":"Established that a tissue-specific elongation factor isoform is non-redundant and essential, reframing translation elongation machinery as developmentally specialized rather than uniform.","evidence":"Genetic deletion mapping and Northern blot of the lethal wasted mouse, showing reciprocal eEF1A1/eEF1A2 expression in heart and muscle","pmids":["9539760"],"confidence":"High","gaps":["Did not define the molecular basis of why eEF1A1 cannot substitute","No structural or biochemical distinction between isoforms shown"]},{"year":2002,"claim":"Showed that an elongation factor can act as a bona fide oncogene, opening the question of how a translation factor drives transformation.","evidence":"Focus formation, anchorage-independent growth, and nude mouse xenografts of eEF1A2-expressing fibroblasts","pmids":["12053177"],"confidence":"High","gaps":["Did not identify the signaling effectors mediating transformation","Did not separate translational from non-translational contributions"]},{"year":2006,"claim":"Identified the PI3K/AKT axis and direct PI4KIIIβ activation as the signaling mechanisms underlying eEF1A2 oncogenicity, distinguishing its moonlighting roles from elongation.","evidence":"siRNA/overexpression with phospho-Akt blots and inhibitors; in vitro lipid kinase assay with purified recombinant eEF1A2 and cellular PI4P measurement","pmids":["17130842","17088255"],"confidence":"High","gaps":["Mechanism by which eEF1A2 activates PI3K not resolved","Did not show whether PI4KIIIβ activation and AKT activation are linked"]},{"year":2007,"claim":"Demonstrated isoform-specific protein partnerships, beginning the dissection of why eEF1A2 (not eEF1A1) confers survival advantages.","evidence":"Yeast two-hybrid and reciprocal co-IP of eEF1A2 with peroxiredoxin I; cell death and caspase assays; transgenic rescue confirming eEF1A2 loss alone causes wasted phenotype","pmids":["16888816","17640869"],"confidence":"High","gaps":["Structural basis of isoform-specific Prdx-I binding not defined","Prdx-I interaction not linked to elongation activity"]},{"year":2010,"claim":"Revealed a non-canonical mRNA-selective translational role, showing eEF1A2 acts as an IRES trans-factor for utrophin A in muscle.","evidence":"RNA-affinity chromatography/MS, UV-crosslinking, IRES reporter assays and transgenic mice; parallel shRNA work linking knockdown to JAK/STAT and PI3K/AKT defects","pmids":["20053670","20505761"],"confidence":"High","gaps":["Sequence/structural determinants of 5'-UTR recognition not mapped","Whether IRES binding uses the tRNA or actin surface unknown"]},{"year":2013,"claim":"Connected eEF1A2 to tumor-suppressor control and downstream proteolytic/metastatic programs, positioning it within established cancer pathways.","evidence":"Yeast two-hybrid and domain mapping of p16(INK4a) interaction with translation reporter assays; siRNA/overexpression with MMP-9 zymography and Akt inhibition in pancreatic cancer","pmids":["23444377","23739844"],"confidence":"Medium","gaps":["p16-eEF1A2 interaction not confirmed by mammalian co-IP","Direct vs indirect control of MMP-9 not established"]},{"year":2016,"claim":"Identified eEF1A2 as the direct molecular target of plitidepsin, providing both a pharmacological tool and a defined binding site on the protein.","evidence":"Binding affinity (KD 80 nM), [14C]-drug pull-down, resistance selection with ectopic rescue, live-cell FLIM-FRET, and molecular modeling of the domain 1/2 interface in GTP conformation","pmids":["27713531"],"confidence":"High","gaps":["Co-crystal structure not solved","Whether drug binding blocks elongation or moonlighting functions not separated"]},{"year":2018,"claim":"Explained the apoptotic consequence of plitidepsin by showing eEF1A2 sequesters and inhibits the pro-apoptotic kinase PKR.","evidence":"Reciprocal co-IP, HPLC-MS, proximity ligation assay, and plitidepsin displacement experiments linking PKR release to MAPK/NF-κB-driven apoptosis","pmids":["30420615"],"confidence":"Medium","gaps":["Stoichiometry and structural basis of PKR sequestration not defined","Single lab; functional consequence shown chemically rather than genetically"]},{"year":2021,"claim":"Resolved how a single protein partitions between elongation and actin functions, showing phosphorylation toggles eEF1A2 between the two activities in dendritic spines.","evidence":"Phosphomutant/phosphomimetic constructs with translation, actin-dynamics, spine-density, and GEF-interaction readouts under mGluR signaling","pmids":["34257105"],"confidence":"High","gaps":["The kinase responsible for spine phosphorylation not identified","Identity of the GEF in this context not molecularly defined"]},{"year":2023,"claim":"Mechanistically connected patient mutations to disease by showing dual disruption of tRNA availability and actin bundling, distinguishing haploinsufficient from gain-of-function alleles.","evidence":"Heterologous expression in HEK293 and cortical neurons with puromycin synthesis, elongation rate, tRNA-binding and actin-bundling assays; prior yeast complementation and zebrafish rescue defining variant effects","pmids":["37695913","32196822","28911200"],"confidence":"High","gaps":["How increased tRNA binding mechanistically slows elongation not fully explained","In vivo neuronal phenotypes of specific gain-of-function alleles not modeled"]},{"year":2024,"claim":"Established post-translational and post-transcriptional regulatory layers controlling eEF1A2 abundance and elongation activity in cancer.","evidence":"KAT8-mediated K408 lactylation with translation/tumor assays; METTL14 m6A and NSUN6 m5C mRNA modifications; SNX16 and A20 ubiquitination control; SIMALR lncRNA enhancing GTPase activity","pmids":["38359291","35013140","37614424","31876369","37399716","39154122"],"confidence":"Medium","gaps":["Interplay between these regulatory marks not integrated","Several mechanisms shown in single labs without independent replication"]},{"year":null,"claim":"How eEF1A2's elongation, IRES-trans-factor, actin-bundling, and signaling activities are coordinated within a single tissue context, and which surface determines each isoform-specific partnership, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of mammalian eEF1A2 with partners","Mechanism switching between elongation and moonlighting functions in vivo unclear","Whether oncogenic signaling depends on elongation activity not definitively separated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[8,29]},{"term_id":"GO:0045182","term_label":"translation regulator activity","supporting_discovery_ids":[7,12,17]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[7,12,19]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[11,12,19]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[4,10]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[11,20]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,6,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,12,17]}],"complexes":["eEF1B complex (eEF1A2-associated)"],"partners":["PI4KB","PRDX1","EIF2AK2","HSP90AB1","CDKN2A","SNX16","TNFAIP3","KAT8"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q05639","full_name":"Elongation factor 1-alpha 2","aliases":["Eukaryotic elongation factor 1 A-2","eEF1A-2","Statin-S1"],"length_aa":463,"mass_kda":50.5,"function":"Translation elongation factor that catalyzes the GTP-dependent binding of aminoacyl-tRNA (aa-tRNA) to the A-site of ribosomes during the elongation phase of protein synthesis. Base pairing between the mRNA codon and the aa-tRNA anticodon promotes GTP hydrolysis, releasing the aa-tRNA from EEF1A1 and allowing its accommodation into the ribosome (By similarity). The growing protein chain is subsequently transferred from the P-site peptidyl tRNA to the A-site aa-tRNA, extending it by one amino acid through ribosome-catalyzed peptide bond formation (By similarity)","subcellular_location":"Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q05639/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EEF1A2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"EEF1G","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/EEF1A2","total_profiled":1310},"omim":[{"mim_id":"620875","title":"FIC DOMAIN-CONTAINING PROTEIN ADENYLYLTRANSFERASE; FICD","url":"https://www.omim.org/entry/620875"},{"mim_id":"617309","title":"IMMUNOGLOBULIN-LIKE AND FIBRONECTIN TYPE III DOMAINS-CONTAINING PROTEIN 1; IGFN1","url":"https://www.omim.org/entry/617309"},{"mim_id":"616409","title":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 33; DEE33","url":"https://www.omim.org/entry/616409"},{"mim_id":"616393","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 38; MRD38","url":"https://www.omim.org/entry/616393"},{"mim_id":"607477","title":"G2- AND S-PHASE EXPRESSED GENE 1; GTSE1","url":"https://www.omim.org/entry/607477"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"heart muscle","ntpm":722.2},{"tissue":"skeletal muscle","ntpm":1827.0}],"url":"https://www.proteinatlas.org/search/EEF1A2"},"hgnc":{"alias_symbol":["EEF1AL","HS1"],"prev_symbol":["STNL","STN"]},"alphafold":{"accession":"Q05639","domains":[{"cath_id":"2.40.30.10","chopping":"246-333_449-461","consensus_level":"high","plddt":90.876,"start":246,"end":461},{"cath_id":"2.40.30.10","chopping":"336-442","consensus_level":"high","plddt":91.5719,"start":336,"end":442}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q05639","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q05639-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q05639-F1-predicted_aligned_error_v6.png","plddt_mean":88.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EEF1A2","jax_strain_url":"https://www.jax.org/strain/search?query=EEF1A2"},"sequence":{"accession":"Q05639","fasta_url":"https://rest.uniprot.org/uniprotkb/Q05639.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q05639/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q05639"}},"corpus_meta":[{"pmid":"38359291","id":"PMC_38359291","title":"KAT8-catalyzed lactylation promotes eEF1A2-mediated protein synthesis and colorectal carcinogenesis.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38359291","citation_count":222,"is_preprint":false},{"pmid":"16207894","id":"PMC_16207894","title":"Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.","date":"2005","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/16207894","citation_count":210,"is_preprint":false},{"pmid":"12053177","id":"PMC_12053177","title":"Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer.","date":"2002","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12053177","citation_count":206,"is_preprint":false},{"pmid":"27679419","id":"PMC_27679419","title":"Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen.","date":"2016","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/27679419","citation_count":173,"is_preprint":false},{"pmid":"8859725","id":"PMC_8859725","title":"Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.","date":"1996","source":"Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/8859725","citation_count":164,"is_preprint":false},{"pmid":"9539760","id":"PMC_9539760","title":"The lethal mutation of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation factor 1alpha, encoded by the Eef1a2 gene.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9539760","citation_count":136,"is_preprint":false},{"pmid":"17130842","id":"PMC_17130842","title":"eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17130842","citation_count":120,"is_preprint":false},{"pmid":"16156888","id":"PMC_16156888","title":"Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours.","date":"2005","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16156888","citation_count":115,"is_preprint":false},{"pmid":"9529064","id":"PMC_9529064","title":"Mutation of invH, but not stn, reduces Salmonella-induced enteritis in cattle.","date":"1998","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9529064","citation_count":110,"is_preprint":false},{"pmid":"22768059","id":"PMC_22768059","title":"Structural and resting state functional connectivity of the subthalamic nucleus: identification of motor STN parts and the hyperdirect pathway.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22768059","citation_count":108,"is_preprint":false},{"pmid":"9924700","id":"PMC_9924700","title":"Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.","date":"1999","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/9924700","citation_count":96,"is_preprint":false},{"pmid":"7553688","id":"PMC_7553688","title":"Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.","date":"1995","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/7553688","citation_count":95,"is_preprint":false},{"pmid":"15606349","id":"PMC_15606349","title":"Vaccination with Theratope (STn-KLH) as treatment for breast cancer.","date":"2004","source":"Expert review of vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/15606349","citation_count":92,"is_preprint":false},{"pmid":"16888816","id":"PMC_16888816","title":"Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress.","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16888816","citation_count":85,"is_preprint":false},{"pmid":"31831633","id":"PMC_31831633","title":"Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer.","date":"2019","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/31831633","citation_count":83,"is_preprint":false},{"pmid":"24285179","id":"PMC_24285179","title":"EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.","date":"2014","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/24285179","citation_count":81,"is_preprint":false},{"pmid":"8812466","id":"PMC_8812466","title":"Assignment of human elongation factor 1alpha genes: EEF1A maps to chromosome 6q14 and EEF1A2 to 20q13.3.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8812466","citation_count":78,"is_preprint":false},{"pmid":"27713531","id":"PMC_27713531","title":"Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27713531","citation_count":74,"is_preprint":false},{"pmid":"20194913","id":"PMC_20194913","title":"Effects of STN stimulation on the initiation and inhibition of saccade in Parkinson disease.","date":"2010","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20194913","citation_count":70,"is_preprint":false},{"pmid":"24697219","id":"PMC_24697219","title":"De novo EEF1A2 mutations in patients with characteristic facial features, intellectual disability, autistic behaviors and epilepsy.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24697219","citation_count":68,"is_preprint":false},{"pmid":"26452038","id":"PMC_26452038","title":"The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26452038","citation_count":67,"is_preprint":false},{"pmid":"10871727","id":"PMC_10871727","title":"Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.","date":"2000","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/10871727","citation_count":67,"is_preprint":false},{"pmid":"21121644","id":"PMC_21121644","title":"Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen.","date":"2011","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/21121644","citation_count":67,"is_preprint":false},{"pmid":"17504999","id":"PMC_17504999","title":"Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17504999","citation_count":66,"is_preprint":false},{"pmid":"17640869","id":"PMC_17640869","title":"Translation elongation factor eEF1A2 is essential for post-weaning survival in mice.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17640869","citation_count":64,"is_preprint":false},{"pmid":"19636410","id":"PMC_19636410","title":"Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19636410","citation_count":62,"is_preprint":false},{"pmid":"20505761","id":"PMC_20505761","title":"Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20505761","citation_count":61,"is_preprint":false},{"pmid":"25744894","id":"PMC_25744894","title":"miR-663 attenuates tumor growth and invasiveness by targeting eEF1A2 in pancreatic cancer.","date":"2015","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25744894","citation_count":61,"is_preprint":false},{"pmid":"16897428","id":"PMC_16897428","title":"Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer.","date":"2006","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/16897428","citation_count":59,"is_preprint":false},{"pmid":"22095224","id":"PMC_22095224","title":"Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression.","date":"2011","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22095224","citation_count":59,"is_preprint":false},{"pmid":"12620150","id":"PMC_12620150","title":"Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.","date":"2003","source":"Clinical breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12620150","citation_count":57,"is_preprint":false},{"pmid":"24151498","id":"PMC_24151498","title":"The major thylakoid protein kinases STN7 and STN8 revisited: effects of altered STN8 levels and regulatory specificities of the STN kinases.","date":"2013","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/24151498","citation_count":57,"is_preprint":false},{"pmid":"23739844","id":"PMC_23739844","title":"eEF1A2 promotes cell migration, invasion and metastasis in pancreatic cancer by upregulating MMP-9 expression through Akt activation.","date":"2013","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/23739844","citation_count":56,"is_preprint":false},{"pmid":"27441201","id":"PMC_27441201","title":"Novel de novo EEF1A2 missense mutations causing epilepsy and intellectual disability.","date":"2016","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27441201","citation_count":51,"is_preprint":false},{"pmid":"17105234","id":"PMC_17105234","title":"Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines.","date":"2006","source":"Bioconjugate chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17105234","citation_count":51,"is_preprint":false},{"pmid":"18816108","id":"PMC_18816108","title":"Synthetic and immunological studies of 5'-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins.","date":"2008","source":"Bioconjugate chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18816108","citation_count":50,"is_preprint":false},{"pmid":"33473168","id":"PMC_33473168","title":"EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-β/SMAD signalling.","date":"2021","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33473168","citation_count":49,"is_preprint":false},{"pmid":"11728222","id":"PMC_11728222","title":"Theratope vaccine (STn-KLH).","date":"2001","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/11728222","citation_count":46,"is_preprint":false},{"pmid":"19723040","id":"PMC_19723040","title":"eEF1A2 as a putative oncogene.","date":"2009","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19723040","citation_count":45,"is_preprint":false},{"pmid":"24853801","id":"PMC_24853801","title":"Up-regulation of eEF1A2 promotes proliferation and inhibits apoptosis in prostate cancer.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24853801","citation_count":45,"is_preprint":false},{"pmid":"8580901","id":"PMC_8580901","title":"Salmonella enterotoxin (stn) gene is prevalent among strains of Salmonella enterica, but not among Salmonella bongori and other Enterobacteriaceae.","date":"1995","source":"FEMS immunology and medical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/8580901","citation_count":45,"is_preprint":false},{"pmid":"14588074","id":"PMC_14588074","title":"The role of protein elongation factor eEF1A2 in ovarian cancer.","date":"2003","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/14588074","citation_count":42,"is_preprint":false},{"pmid":"17241358","id":"PMC_17241358","title":"Real-time PCR method for Salmonella spp. targeting the stn gene.","date":"2007","source":"Journal of applied microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17241358","citation_count":38,"is_preprint":false},{"pmid":"19138673","id":"PMC_19138673","title":"Regulation and functional role of eEF1A2 in pancreatic carcinoma.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19138673","citation_count":38,"is_preprint":false},{"pmid":"37852428","id":"PMC_37852428","title":"Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinoma.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37852428","citation_count":34,"is_preprint":false},{"pmid":"32196822","id":"PMC_32196822","title":"Damaging de novo missense variants in EEF1A2 lead to a developmental and degenerative epileptic-dyskinetic encephalopathy.","date":"2020","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/32196822","citation_count":34,"is_preprint":false},{"pmid":"33358727","id":"PMC_33358727","title":"Experimental investigation into the role of the subthalamic nucleus (STN) in motor control using optogenetics in mice.","date":"2020","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/33358727","citation_count":34,"is_preprint":false},{"pmid":"10370638","id":"PMC_10370638","title":"Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.","date":"1999","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/10370638","citation_count":34,"is_preprint":false},{"pmid":"17088255","id":"PMC_17088255","title":"Binding of elongation factor eEF1A2 to phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and phosphatidylinositol 4-phosphate generation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17088255","citation_count":33,"is_preprint":false},{"pmid":"30420615","id":"PMC_30420615","title":"Binding of eEF1A2 to the RNA-dependent protein kinase PKR modulates its activity and promotes tumour cell survival.","date":"2018","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30420615","citation_count":32,"is_preprint":false},{"pmid":"35013140","id":"PMC_35013140","title":"METTL14 promotes apoptosis of spinal cord neurons by inducing EEF1A2 m6A methylation in spinal cord injury.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35013140","citation_count":32,"is_preprint":false},{"pmid":"23444377","id":"PMC_23444377","title":"Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction.","date":"2013","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/23444377","citation_count":32,"is_preprint":false},{"pmid":"14499607","id":"PMC_14499607","title":"The stn-1 syntrophin gene of C.elegans is functionally related to dystrophin and dystrobrevin.","date":"2003","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14499607","citation_count":32,"is_preprint":false},{"pmid":"32370811","id":"PMC_32370811","title":"Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.","date":"2020","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/32370811","citation_count":32,"is_preprint":false},{"pmid":"26682508","id":"PMC_26682508","title":"Two cases of early-onset myoclonic seizures with continuous parietal delta activity caused by EEF1A2 mutations.","date":"2015","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/26682508","citation_count":32,"is_preprint":false},{"pmid":"34203525","id":"PMC_34203525","title":"On the Need to Tell Apart Fraternal Twins eEF1A1 and eEF1A2, and Their Respective Outfits.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34203525","citation_count":31,"is_preprint":false},{"pmid":"17437010","id":"PMC_17437010","title":"Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus.","date":"2007","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17437010","citation_count":31,"is_preprint":false},{"pmid":"31876369","id":"PMC_31876369","title":"SNX16 activates c-Myc signaling by inhibiting ubiquitin-mediated proteasomal degradation of eEF1A2 in colorectal cancer development.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31876369","citation_count":31,"is_preprint":false},{"pmid":"18791240","id":"PMC_18791240","title":"unc-44 Ankyrin and stn-2 gamma-syntrophin regulate sax-7 L1CAM function in maintaining neuronal positioning in Caenorhabditis elegans.","date":"2008","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18791240","citation_count":31,"is_preprint":false},{"pmid":"28911200","id":"PMC_28911200","title":"Homozygous EEF1A2 mutation causes dilated cardiomyopathy, failure to thrive, global developmental delay, epilepsy and early death.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28911200","citation_count":30,"is_preprint":false},{"pmid":"20053670","id":"PMC_20053670","title":"The utrophin A 5'-UTR drives cap-independent translation exclusively in skeletal muscles of transgenic mice and interacts with eEF1A2.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20053670","citation_count":30,"is_preprint":false},{"pmid":"19909265","id":"PMC_19909265","title":"eEF1A2 and neuronal degeneration.","date":"2009","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/19909265","citation_count":29,"is_preprint":false},{"pmid":"19094180","id":"PMC_19094180","title":"Loss of translation elongation factor (eEF1A2) expression in vivo differentiates between Wallerian degeneration and dying-back neuronal pathology.","date":"2008","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/19094180","citation_count":27,"is_preprint":false},{"pmid":"31719620","id":"PMC_31719620","title":"Products of Chemoenzymatic Synthesis Representing MUC1 Tandem Repeat Unit with T-, ST- or STn-antigen Revealed Distinct Specificities of Anti-MUC1 Antibodies.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31719620","citation_count":27,"is_preprint":false},{"pmid":"22301710","id":"PMC_22301710","title":"Salmonella enterotoxin (Stn) regulates membrane composition and integrity.","date":"2012","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/22301710","citation_count":26,"is_preprint":false},{"pmid":"12620152","id":"PMC_12620152","title":"The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).","date":"2003","source":"Clinical breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12620152","citation_count":25,"is_preprint":false},{"pmid":"10659368","id":"PMC_10659368","title":"Sips, Sops, and SPIs but not stn influence Salmonella enteropathogenesis.","date":"1999","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/10659368","citation_count":25,"is_preprint":false},{"pmid":"34257105","id":"PMC_34257105","title":"The elongation factor eEF1A2 controls translation and actin dynamics in dendritic spines.","date":"2021","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/34257105","citation_count":24,"is_preprint":false},{"pmid":"28378778","id":"PMC_28378778","title":"Biallelic mutations in the gene encoding eEF1A2 cause seizures and sudden death in F0 mice.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28378778","citation_count":24,"is_preprint":false},{"pmid":"32275913","id":"PMC_32275913","title":"Effects of eEF1A2 knockdown on autophagy in an MPP+-induced cellular model of Parkinson's disease.","date":"2020","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/32275913","citation_count":24,"is_preprint":false},{"pmid":"24594592","id":"PMC_24594592","title":"Construction and validation of a Sambucus nigra biosensor for cancer-associated STn antigen.","date":"2014","source":"Biosensors & bioelectronics","url":"https://pubmed.ncbi.nlm.nih.gov/24594592","citation_count":24,"is_preprint":false},{"pmid":"16891156","id":"PMC_16891156","title":"Prevalence of virulence genes (ctxA, stn, OmpW and tcpA) among non-O1 Vibrio cholerae isolated from fresh water environment.","date":"2006","source":"International journal of hygiene and environmental health","url":"https://pubmed.ncbi.nlm.nih.gov/16891156","citation_count":24,"is_preprint":false},{"pmid":"24220286","id":"PMC_24220286","title":"Highly homologous eEF1A1 and eEF1A2 exhibit differential post-translational modification with significant enrichment around localised sites of sequence variation.","date":"2013","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/24220286","citation_count":24,"is_preprint":false},{"pmid":"25679360","id":"PMC_25679360","title":"Synthetic and immunological studies of N-acyl modified S-linked STn derivatives as anticancer vaccine candidates.","date":"2015","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25679360","citation_count":24,"is_preprint":false},{"pmid":"12620151","id":"PMC_12620151","title":"Clinical development of the STn-KLH vaccine (Theratope).","date":"2003","source":"Clinical breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12620151","citation_count":23,"is_preprint":false},{"pmid":"18661515","id":"PMC_18661515","title":"The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas.","date":"2008","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18661515","citation_count":23,"is_preprint":false},{"pmid":"24342106","id":"PMC_24342106","title":"Emotion recognition in Parkinson's disease after subthalamic deep brain stimulation: differential effects of microlesion and STN stimulation.","date":"2013","source":"Cortex; a journal devoted to the study of the nervous system and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/24342106","citation_count":23,"is_preprint":false},{"pmid":"32332749","id":"PMC_32332749","title":"Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32332749","citation_count":22,"is_preprint":false},{"pmid":"21851817","id":"PMC_21851817","title":"The lipid kinase PI4KIIIβ and the eEF1A2 oncogene co-operate to disrupt three-dimensional in vitro acinar morphogenesis.","date":"2011","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21851817","citation_count":22,"is_preprint":false},{"pmid":"33472823","id":"PMC_33472823","title":"Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS.","date":"2021","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33472823","citation_count":22,"is_preprint":false},{"pmid":"39154122","id":"PMC_39154122","title":"Ac4C modification of lncRNA SIMALR promotes nasopharyngeal carcinoma progression through activating eEF1A2 to facilitate ITGB4/ITGA6 translation.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39154122","citation_count":21,"is_preprint":false},{"pmid":"37399716","id":"PMC_37399716","title":"Biliverdin modulates the Nrf2/A20/eEF1A2 axis to alleviate cerebral ischemia-reperfusion injury by inhibiting pyroptosis.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37399716","citation_count":21,"is_preprint":false},{"pmid":"21691430","id":"PMC_21691430","title":"Synthetic and Immunological Studies of sTn Derivatives Carrying 5-N-(p-Substituted Phenylacetyl)Sialic Acid for the Development of Effective Cancer Vaccines.","date":"2011","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/21691430","citation_count":21,"is_preprint":false},{"pmid":"10950927","id":"PMC_10950927","title":"The human elongation factor 1 A-2 gene (EEF1A2): complete sequence and characterization of gene structure and promoter activity.","date":"2000","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10950927","citation_count":19,"is_preprint":false},{"pmid":"25436608","id":"PMC_25436608","title":"Characterisation of translation elongation factor eEF1B subunit expression in mammalian cells and tissues and co-localisation with eEF1A2.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25436608","citation_count":19,"is_preprint":false},{"pmid":"33035587","id":"PMC_33035587","title":"EEF1A2 triggers stronger ERK mediated metastatic program in ER negative breast cancer cells than in ER positive cells.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33035587","citation_count":19,"is_preprint":false},{"pmid":"21277605","id":"PMC_21277605","title":"Prevalence of multiple drug resistance and screening of enterotoxin (stn) gene in Salmonella enterica serovars from water sources in Lagos, Nigeria.","date":"2011","source":"Public health","url":"https://pubmed.ncbi.nlm.nih.gov/21277605","citation_count":19,"is_preprint":false},{"pmid":"10573653","id":"PMC_10573653","title":"Prevalence of enterotoxin gene (stn) among different serovars of Salmonella.","date":"1999","source":"The Indian journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/10573653","citation_count":19,"is_preprint":false},{"pmid":"27380866","id":"PMC_27380866","title":"Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines.","date":"2016","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27380866","citation_count":19,"is_preprint":false},{"pmid":"37614424","id":"PMC_37614424","title":"Loss of NSUN6 inhibits osteosarcoma progression by downregulating EEF1A2 expression and activation of Akt/mTOR signaling pathway via m5C methylation.","date":"2023","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37614424","citation_count":17,"is_preprint":false},{"pmid":"27483363","id":"PMC_27483363","title":"Comparison of the ability of mammalian eEF1A1 and its oncogenic variant eEF1A2 to interact with actin and calmodulin.","date":"2017","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27483363","citation_count":17,"is_preprint":false},{"pmid":"32437650","id":"PMC_32437650","title":"The Fastest Way to Stop: Inhibitory Control and IFG-STN Hyperdirect Connectivity.","date":"2020","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/32437650","citation_count":17,"is_preprint":false},{"pmid":"16277348","id":"PMC_16277348","title":"Synthesis of double C-glycoside analogue of sTn.","date":"2005","source":"The Journal of organic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16277348","citation_count":17,"is_preprint":false},{"pmid":"27153166","id":"PMC_27153166","title":"Implantation of autologous peripheral nerve grafts into the substantia nigra of subjects with idiopathic Parkinson's disease treated with bilateral STN DBS: a report of safety and feasibility.","date":"2016","source":"Journal of neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/27153166","citation_count":17,"is_preprint":false},{"pmid":"37673911","id":"PMC_37673911","title":"Molecular architecture and electron transfer pathway of the Stn family transhydrogenase.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37673911","citation_count":16,"is_preprint":false},{"pmid":"22848658","id":"PMC_22848658","title":"Haploinsufficiency for translation elongation factor eEF1A2 in aged mouse muscle and neurons is compatible with normal function.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22848658","citation_count":16,"is_preprint":false},{"pmid":"38012382","id":"PMC_38012382","title":"EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia.","date":"2023","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38012382","citation_count":15,"is_preprint":false},{"pmid":"26543859","id":"PMC_26543859","title":"Efficient and Specific Detection of Salmonella in Food Samples Using a stn-Based Loop-Mediated Isothermal Amplification Method.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/26543859","citation_count":15,"is_preprint":false},{"pmid":"33079080","id":"PMC_33079080","title":"Rhamnose modified bovine serum albumin as a carrier protein promotes the immune response against sTn antigen.","date":"2020","source":"Chemical communications (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33079080","citation_count":15,"is_preprint":false},{"pmid":"37695913","id":"PMC_37695913","title":"Autism- and epilepsy-associated EEF1A2 mutations lead to translational dysfunction and altered actin bundling.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37695913","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47813,"output_tokens":8995,"usd":0.139182,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18957,"output_tokens":4350,"usd":0.101767,"stage2_stop_reason":"end_turn"},"total_usd":0.240949,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"The lethal wasted (wst) mouse phenotype is caused by a 15.8 kb deletion that abolishes expression of Eef1a2, a tissue-specific translation elongation factor. eEF1A2 expression is reciprocal with eEF1A1 in heart and muscle postnatally, establishing that tissue-specific isoforms of the translation elongation apparatus are essential for postnatal survival.\",\n      \"method\": \"Genetic deletion mapping, Northern blot expression analysis, in vivo mouse genetics\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — precise genetic deletion identified, reciprocal expression pattern established, causal link confirmed by transgenic rescue experiments in subsequent work; independently replicated across multiple labs\",\n      \"pmids\": [\"9539760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Transgenic rescue experiments established that loss of eEF1A2 function alone is responsible for all abnormalities in wasted mice, including motor neuron degeneration. eEF1A2 is expressed at high levels in specific cell types including pancreatic islet cells and enteroendocrine cells. Expression of eEF1A1 and eEF1A2 is mutually exclusive in individual cell types, and the motor neuron degeneration phenotype relates precisely to the relative expression of the two isoforms.\",\n      \"method\": \"Transgenic rescue, anti-peptide antibody immunohistochemistry, cell-type-specific expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transgenic rescue is definitive functional test, multiple orthogonal methods, causal conclusion firmly established\",\n      \"pmids\": [\"17640869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"EEF1A2 has oncogenic properties: it enhances focus formation, allows anchorage-independent growth, decreases doubling time of rodent fibroblasts, and makes NIH3T3 fibroblasts tumorigenic in nude mice, establishing EEF1A2 as a functional oncogene.\",\n      \"method\": \"Focus formation assay, anchorage-independent growth assay, xenograft tumor model\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple functional oncogenicity assays in vitro and in vivo, independently replicated in subsequent studies\",\n      \"pmids\": [\"12053177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"eEF1A2 expression is sufficient to activate Akt in a PI3K-dependent manner, stimulate filopodia formation dependent on PI3K, ROCK, and Akt kinases, and promote cell migration and invasion in breast cancer cells. siRNA-mediated reduction of eEF1A2 reduces Akt activity.\",\n      \"method\": \"siRNA knockdown, Western blot for phospho-Akt, filopodia imaging, migration/invasion assays with kinase inhibitors\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function experiments with multiple pathway inhibitors and cellular readouts, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"17130842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"eEF1A2 directly binds to and activates phosphatidylinositol 4-kinase IIIβ (PI4KIIIβ). Purified recombinant eEF1A2 increases PI4KIIIβ lipid kinase activity in vitro, and eEF1A2 expression in cells increases cellular PI4-kinase activity and intracellular phosphatidylinositol 4-phosphate abundance. siRNA knockdown of eEF1A2 concomitantly reduces PI4-kinase activity.\",\n      \"method\": \"In vitro lipid kinase assay with purified recombinant proteins, siRNA knockdown, cellular PI4P measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified proteins plus cellular gain/loss-of-function confirmation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"17088255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mouse eEF1A2 interacts with peroxiredoxin I (Prdx-I) but not with its isoform eEF1A1. The eEF1A2–Prdx-I complex confers resistance to peroxide-induced cell death, reducing activation of caspases 3 and 8 and increasing Akt expression. This interaction is isoform-specific.\",\n      \"method\": \"Yeast two-hybrid screening, co-immunoprecipitation from cells and mouse tissues, double transfectant cell death assays, caspase activation assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP from multiple sources confirms interaction; isoform specificity validated; functional consequence shown in cells; single lab\",\n      \"pmids\": [\"16888816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"EEF1A2 acts as an upstream inducer of PI3K to support MDM4 stabilization in hepatocellular carcinoma. The EEF1A2/PI3K/AKT/mTOR axis promotes protumorigenic stabilization of MDM4 via post-transcriptional mechanism, inactivating p53. EEF1A2, phosphorylated AKT, and MDM4 expression are strongly correlated (each rho >0.8) in human HCC.\",\n      \"method\": \"Silencing and overexpression experiments in HCC cell lines, PI3K/AKT/mTOR pathway inhibition, Western blot, in vivo AKT mouse model, human HCC tissue correlation analysis\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway placement by epistasis with multiple inhibitors, in vivo model, human tissue validation; single lab, pathway mechanism partially inferred\",\n      \"pmids\": [\"24285179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"eEF1A2 binds the 5'-UTR of utrophin A mRNA and promotes IRES-dependent (cap-independent) translation specifically in skeletal muscle. RNA-affinity chromatography identified eEF1A2 as a trans-factor binding the utrophin A 5'-UTR; UV-crosslinking confirmed specificity. Cells lacking eEF1A2 had reduced IRES activity, while eEF1A2 overexpression increased it.\",\n      \"method\": \"RNA-affinity chromatography combined with mass spectrometry, UV-crosslinking, IRES reporter assays in cultured cells, transgenic mice\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — biochemical identification plus functional IRES assay and in vivo transgenic confirmation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"20053670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"eEF1A2 is the primary anticancer target of plitidepsin. The drug interacts with eEF1A2 with a KD of 80 nM. Tumor cell lines selected for ≥100-fold plitidepsin resistance show reduced eEF1A2 protein levels; ectopic eEF1A2 expression in resistant cells restores plitidepsin sensitivity. FLIM-phasor FRET experiments demonstrate drug-protein complex formation in living cells. Molecular modelling identifies a binding site at the interface of domains 1 and 2 of eEF1A2 in the GTP conformation.\",\n      \"method\": \"Binding affinity measurements, [14C]-plitidepsin cell lysate pull-down, resistance selection, ectopic expression rescue, FLIM-phasor FRET in living cells, molecular modelling\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical and cellular methods including direct binding measurement, genetic rescue, and live-cell FRET; robust mechanistic evidence\",\n      \"pmids\": [\"27713531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Tumor suppressor p16(INK4a) directly interacts with eEF1A2 (identified by yeast two-hybrid), binding all domains except D2 (250–327 aa). Ectopic p16(INK4a) expression decreases eEF1A2 expression and suppresses protein synthesis as measured by luciferase reporter activity. Microinjection of p16(INK4a) mRNA into Xenopus embryos suppressed luciferase mRNA translation, and combined p16(INK4a) plus morpholino-eEF1A2 further reduced translational activity.\",\n      \"method\": \"Yeast two-hybrid, domain mapping, luciferase reporter translation assay, Xenopus embryo microinjection with morpholino knockdown\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus functional translation assays in two model systems; interaction not confirmed by co-IP in mammalian cells; single lab\",\n      \"pmids\": [\"23444377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"eEF1A2 binds to double-stranded RNA-activated protein kinase (PKR), inhibiting its pro-apoptotic kinase activity likely through sequestration. Targeting eEF1A2 with plitidepsin releases PKR from the complex, facilitating PKR activation, triggering MAPK signaling and NF-κB-dependent extrinsic apoptosis, leading to tumor cell death.\",\n      \"method\": \"Co-immunoprecipitation, HPLC-mass spectrometry, proximity ligation assay, plitidepsin displacement experiments, cell death assays\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP plus proximity ligation assay confirm interaction; functional consequence shown by chemical displacement; single lab\",\n      \"pmids\": [\"30420615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Phosphorylation of isoform-specific sites in eEF1A2 coordinates translation and actin dynamics in dendritic spines. A nonphosphorylatable eEF1A2 mutant stimulates mRNA translation but reduces actin dynamics and spine density. A phosphomimetic mutant exhibits decreased F-actin association and is inactive as a translation elongation factor. Metabotropic glutamate receptor signaling triggers transient phosphorylation-dependent dissociation of eEF1A2 from its guanine exchange factor in dendritic spines.\",\n      \"method\": \"Phosphomutant/phosphomimetic expression, translation assays, actin dynamics imaging, dendritic spine density quantification, mGluR signaling experiments with co-localization\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple mutant constructs with orthogonal readouts (translation, actin, spine morphology, GEF interaction), mechanistic model experimentally validated\",\n      \"pmids\": [\"34257105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Three patient-associated EEF1A2 mutations (G70S, E122K, D252H) decrease de novo protein synthesis and elongation rates in HEK293 cells. In mouse cortical neurons these mutations decrease protein synthesis and alter neuronal morphology independently of endogenous eEF1A2 levels, indicating toxic gain-of-function. Mutant eEF1A2 proteins display increased tRNA binding and decreased actin-bundling activity, suggesting dual disruption of tRNA availability and actin cytoskeleton.\",\n      \"method\": \"Heterologous expression in HEK293 cells and mouse cortical neurons, puromycin incorporation (de novo synthesis assay), elongation rate measurement, tRNA binding assay, actin-bundling assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple patient mutations tested with in vitro biochemical assays (tRNA binding, actin bundling) plus cellular translation assays; mechanistic conclusions supported by multiple orthogonal methods\",\n      \"pmids\": [\"37695913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Three-dimensional homology models of eEF1A1 and eEF1A2 based on yeast eEF1A crystal structure reveal that nearly all variant surface-exposed residues lie in two proximal but distinct sub-clusters on one face of the protein. No buried residue differences are predicted to affect protein fold or domain-domain interactions. Predicted variant-specific phosphorylation sites may explain functional differences between the two isoforms.\",\n      \"method\": \"Comparative 3D homology modelling validated against yeast crystal structure, surface electrostatic and lipophilic property analysis, sequence-based phosphorylation prediction\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — structural modelling with validation but no mutagenesis or direct experimental confirmation of predicted sites; predictions provide testable hypotheses\",\n      \"pmids\": [\"19636410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"eEF1A2 promotes cell migration, invasion, and peritoneal metastasis in pancreatic cancer through upregulation of MMP-9 expression and activity. This effect is dependent on eEF1A2-induced Akt activation; inhibition of MMP-9 activity or Akt reduces the promoting effect of eEF1A2 on cell migration and invasion.\",\n      \"method\": \"siRNA knockdown, ectopic overexpression, migration/invasion assays, MMP-9 activity assay (gelatin zymography), Akt inhibition, in vivo peritoneal metastasis mouse model\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function with multiple downstream readouts and pathway inhibition; single lab\",\n      \"pmids\": [\"23739844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"shRNA-mediated knockdown of Eef1a2 in mouse plasmacytomas causes growth inhibition from delayed G1-S progression and apoptosis under serum-starved conditions. Transcriptional profiling and Western blot reveal impaired JAK/STAT and PI3K/AKT signaling as downstream consequences of Eef1a2 knockdown.\",\n      \"method\": \"shRNA knockdown, flow cytometry cell cycle analysis, apoptosis assay, transcriptional profiling, Western blot for JAK/STAT and PI3K/AKT pathway components\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean knockdown with defined cell cycle and pathway readouts; single lab, no rescue experiment\",\n      \"pmids\": [\"20505761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EEF1A2 interacts with HSP90AB1 (Hsp90β) to increase TGF-β receptor I and II expression, enhancing SMAD3 phosphorylation and nuclear localization, thereby promoting epithelial-mesenchymal transition and metastasis of lung adenocarcinoma cells.\",\n      \"method\": \"LC-MS/MS proteomics identification of binding partners, co-immunoprecipitation, immunofluorescence co-localization, in vitro and in vivo metastasis assays, Western blot for TGF-β signaling components\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding partner identified by mass spectrometry and confirmed by reciprocal co-IP; pathway downstream effects demonstrated; single lab\",\n      \"pmids\": [\"33473168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Heterozygous de novo EEF1A2 variants are functionally validated as protein-damaging using heterologous expression and complementation analysis in yeast. Pathogenic variants disrupt both the protein synthesis and integrated stress response functions of eEF1A2, and appear to act via haploinsufficiency.\",\n      \"method\": \"Heterologous expression, yeast complementation assay, functional translation assays\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro/yeast functional validation of multiple patient variants with complementation; single study, mechanism partially inferred\",\n      \"pmids\": [\"32196822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In zebrafish, eef1a2 deficiency (morpholino knockdown) causes skeletal muscle weakness, cardiac failure, and small heads. Human wild-type EEF1A2 mRNA rescues the morphant phenotype, but the pathogenic p.P333L mutant RNA does not, confirming that the mutation impairs eEF1A2 function. In yeast, previously identified de novo mutations fail to complement eEF1A ortholog deletion (growth defect), while p.P333L causes a milder growth defect without dominant-negative effect.\",\n      \"method\": \"Zebrafish morpholino knockdown, mRNA rescue experiment, yeast complementation assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — two independent model systems (zebrafish and yeast) with rescue experiments; wild-type vs. mutant mRNA discrimination establishes functional deficit\",\n      \"pmids\": [\"28911200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"eEF1A1 (but not eEF1A2) binds calmodulin, which interferes with eEF1A1's tRNA-binding and actin-bundling activities in vitro. Both isoforms exhibit actin-bundling activity but form morphologically distinct bundle types. eEF1A2 cannot be controlled by Ca2+-mediated regulatory systems through calmodulin.\",\n      \"method\": \"In vitro binding assays, actin-bundling assay, tRNA-binding assay, calmodulin pull-down\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro biochemical assays comparing both isoforms; single lab; no cellular validation of calmodulin-independence\",\n      \"pmids\": [\"27483363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The eEF1B complex subunits (eEF1Bα, eEF1Bδ, eEF1Bγ) co-localize with both eEF1A1 and eEF1A2 in sufficiently close proximity to suggest complex formation. Ablation of any eEF1B subunit in human cell lines has a small but significant impact on cell viability and cycling.\",\n      \"method\": \"Co-localization immunofluorescence/proximity assay, siRNA knockdown of eEF1B subunits, cell viability and cell cycle assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — co-localization supports but does not definitively prove physical interaction of eEF1A2 with eEF1B; no biochemical pull-down for eEF1A2-eEF1B shown\",\n      \"pmids\": [\"25436608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Transient overexpression of eEF1A2 in mouse muscles increases IRES-mediated translation of utrophin A. FDA-approved drugs that increase eEF1A2 protein levels also upregulate utrophin A, and treatment of mdx mice with two top lead compounds improves the dystrophic phenotype, establishing eEF1A2-driven IRES translation of utrophin A as a therapeutically relevant mechanism.\",\n      \"method\": \"Transient overexpression in mouse muscle, IRES reporter assay, ELISA-based high-throughput drug screen, mdx mouse treatment with phenotypic assessment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo overexpression with direct IRES reporter readout, confirmed in disease model; multiple orthogonal methods including drug screen and in vivo rescue\",\n      \"pmids\": [\"32332749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"eEF1A2 expression phenocopies PI4KIIIβ in disrupting three-dimensional mammary acinar morphogenesis. Both eEF1A2 and PI4KIIIβ alter intracellular localization of PI(4)P and PI(4,5)P2 within acini, indicating that eEF1A2-mediated PI4P generation is relevant to mammary neoplasia.\",\n      \"method\": \"3D acinar morphogenesis assay in MCF10A cells, PI(4)P and PI(4,5)P2 localization by immunofluorescence, ectopic expression of eEF1A2 and PI4KIIIβ\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cellular morphogenesis assay with lipid localization readout; consistent with known eEF1A2-PI4KIIIβ biochemical interaction; single lab\",\n      \"pmids\": [\"21851817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"KAT8 acts as a pan-lysine lactyltransferase (Kla writer) responsible for installing lactylation on eEF1A2 at K408. Lactylation of eEF1A2-K408 boosts translation elongation and enhances protein synthesis, contributing to colorectal carcinogenesis. Deletion of KAT8 inhibits CRC tumor growth, especially in a high-lactic tumor microenvironment.\",\n      \"method\": \"Global lactylation profiling in CRC, screening of eEF1A2-interacting proteins, KAT8 identification as lactyltransferase, site-specific lactylation at K408, in vitro and in vivo translation/tumor growth assays, KAT8 deletion experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-specific PTM identified with functional translation readout and in vivo tumor model; single lab, KAT8 mechanism partially characterized\",\n      \"pmids\": [\"38359291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"METTL14-mediated m6A modification of EEF1A2 mRNA decreases EEF1A2 expression. Silencing METTL14 inhibits m6A modification of EEF1A2, increases EEF1A2 protein levels, and activates the Akt/mTOR pathway to promote spinal cord neuron survival. Overexpression of EEF1A2 promotes neuron viability and inhibits apoptosis via Akt/mTOR activation.\",\n      \"method\": \"m6A methylation assay, METTL14 silencing/overexpression, EEF1A2 overexpression, Western blot for Akt/mTOR pathway, apoptosis and viability assays in rat SCI model\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — m6A writer identified with causal link to EEF1A2 expression and downstream pathway activation; single lab, pathway placement by epistasis\",\n      \"pmids\": [\"35013140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SNX16 interacts with eEF1A2 and inhibits its ubiquitination and proteasomal degradation, leading to eEF1A2 protein stabilization and downstream activation of c-Myc signaling in colorectal cancer.\",\n      \"method\": \"Co-immunoprecipitation of SNX16-eEF1A2 complex, ubiquitination assay, proteasome inhibitor experiments, c-Myc pathway analysis by Western blot\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP confirms interaction, ubiquitination assay shows mechanistic regulation of eEF1A2 stability; single lab\",\n      \"pmids\": [\"31876369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A20 interacts with eEF1A2 through its ZnF4 domain to ubiquitinate and degrade eEF1A2. Nrf2 transcriptionally regulates A20 expression by binding its promoter. This Nrf2/A20/eEF1A2 axis modulates NF-κB pathway activity and regulates pyroptosis in cerebral ischemia-reperfusion injury.\",\n      \"method\": \"Co-immunoprecipitation, dual-luciferase reporter assay, chromatin immunoprecipitation, gene overexpression/silencing experiments, Western blot\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus ChIP and luciferase assay define pathway; domain-level interaction mapped; single lab\",\n      \"pmids\": [\"37399716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NSUN6 methylates EEF1A2 mRNA at m5C sites and increases mRNA stability in an m5C-dependent manner, thereby upregulating EEF1A2 expression and activating the Akt/mTOR signaling pathway in osteosarcoma.\",\n      \"method\": \"RNA immunoprecipitation (RIP), methylated RIP assay, NSUN6 knockdown/overexpression, mRNA stability assay, Western blot for Akt/mTOR pathway\",\n      \"journal\": \"Experimental and therapeutic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — m5C writer identified with mRNA stability readout and downstream pathway; single lab\",\n      \"pmids\": [\"37614424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Loss of eEF1A2 expression in motor neurons of wasted mice triggers dying-back neuropathy with synaptic loss at the neuromuscular junction preceding axonal pathology, morphologically distinct from Wallerian degeneration. Loss of eEF1A2 also significantly delays Wallerian degeneration after nerve lesion, and correlates with reduced ZPR1 expression.\",\n      \"method\": \"In vivo neuromuscular junction morphology analysis, tibial nerve lesion model, immunohistochemistry for eEF1A2 and ZPR1, comparison of wasted vs. wild-type mice\",\n      \"journal\": \"Journal of anatomy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined in vivo phenotype with mechanistic distinction between two degeneration pathways using genetic model; single lab\",\n      \"pmids\": [\"19094180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SIMALR lncRNA binds eEF1A2 and enhances its endogenous GTPase activity. SIMALR further mediates activation of eEF1A2 phosphorylation to accelerate translation of ITGB4/ITGA6 mRNAs, promoting NPC malignant phenotype.\",\n      \"method\": \"RNA-binding assay (SIMALR-eEF1A2 interaction), GTPase activity assay, phosphorylation analysis, polysome profiling for target mRNA translation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — abstract describes GTPase activity enhancement and phosphorylation promotion; mechanistic details of RNA-protein interaction and specific assay methods not fully described in abstract\",\n      \"pmids\": [\"39154122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EEF1A2 acts as an RNA-binding protein/transcriptional co-factor that cooperates with circ-CDYL to initiate COL14A1 transcription in hepatocellular carcinoma cancer stem cells, promoting ERK signaling and EMT-driven lung metastasis.\",\n      \"method\": \"Mechanistic studies identifying EEF1A2 as transcriptional co-factor with circ-CDYL; COL14A1 transcription assay; ERK signaling pathway analysis\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — non-canonical transcriptional co-factor role described for EEF1A2 but experimental details are sparse in abstract; single study\",\n      \"pmids\": [\"37852428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ZNF217-induced neoplastic properties in ovarian surface epithelial cells are mediated through eEF1A2: siRNA targeting eEF1A2 efficiently inhibits both anchorage independence and resistance to apoptosis conferred by ZNF217 overexpression, placing eEF1A2 downstream of ZNF217 in this oncogenic pathway.\",\n      \"method\": \"Lentiviral overexpression, siRNA knockdown, anchorage-independent growth assay, apoptosis resistance assay, array CGH, SNP analysis\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by siRNA rescue of ZNF217 phenotype; multiple oncogenicity assays; single lab\",\n      \"pmids\": [\"18661515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"eEF1A2 knockdown in MPP+-treated dopaminergic cells decreases autophagy markers (LC3-II/LC3-I ratio, LC3 puncta, phospho-Beclin-1), reduces mitophagy, aggravates α-synuclein accumulation, and increases apoptosis, indicating eEF1A2 is required for autophagic flux and dopaminergic neuron survival under oxidative stress.\",\n      \"method\": \"eEF1A2 siRNA knockdown in differentiated SH-SY5Y cells with MPP+ treatment, LC3 immunofluorescence, mitochondrial membrane potential assay, caspase-3/7 activation assay\",\n      \"journal\": \"Neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean knockdown with multiple autophagy readouts; single lab, no rescue experiment\",\n      \"pmids\": [\"32275913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EEF1A2 promotes HIF1A expression via ERK-Myc and mTOR signaling under normoxia, and hypoxia induces EEF1A2 expression; HIF1A binds the EEF1A2 promoter and induces its transcription, creating a positive feedback loop. EEF1A2 positively affects VEGF transcription and translation, increasing VEGF release to activate ERK and PI3K-AKT signaling in endothelial cells.\",\n      \"method\": \"Luciferase assay and EMSA confirming HIF1A binding to EEF1A2 promoter, RT-PCR, polysome profiling for VEGF translation, angiogenesis assays (CAM, tubulogenesis, aortic ring, Matrigel plug)\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — EMSA and luciferase assay provide direct evidence for HIF1A-eEF1A2 promoter binding; polysome profiling for translational regulation; multiple in vivo angiogenesis models; single lab\",\n      \"pmids\": [\"38012382\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"eEF1A2 is a tissue-specific translation elongation factor (restricted to neurons, cardiomyocytes, and muscle) that delivers aminoacyl-tRNAs to the ribosome A-site in a GTP-dependent manner; beyond canonical translation, it activates PI3K/AKT and JAK/STAT oncogenic signaling, directly binds and activates PI4KIIIβ to generate PI(4)P, interacts with peroxiredoxin I to confer oxidative stress resistance, sequesters and inhibits the pro-apoptotic kinase PKR, promotes IRES-dependent translation of utrophin A in muscle, coordinates actin dynamics and spine structural plasticity through phosphorylation-dependent dissociation from its GEF, and is subject to post-translational regulation including lactylation at K408 (installed by KAT8), m6A methylation (by METTL14), m5C methylation (by NSUN6), ubiquitination (regulated by SNX16 and A20), and phosphorylation at isoform-specific sites that toggle its activity between translation elongation and actin bundling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"EEF1A2 is a tissue-restricted isoform of the translation elongation factor eEF1A whose expression is reciprocal with eEF1A1 and is essential for postnatal survival of neurons and muscle, as established by the lethal motor neuron degeneration of the Eef1a2-null wasted mouse and its rescue by transgenic eEF1A2 [#0, #1, #28]. In its canonical role it delivers aminoacyl-tRNAs during elongation, an activity directly demonstrated through tRNA-binding and de novo synthesis assays of patient mutants and through complementation of yeast eEF1A deletion [#12, #17, #18]. Beyond bulk elongation, eEF1A2 binds the utrophin A 5'-UTR to drive cap-independent (IRES) translation specifically in skeletal muscle, a mechanism that can be pharmacologically exploited to improve the dystrophic phenotype of mdx mice [#7, #21]. eEF1A2 has a second, isoform-specific cytoskeletal function as an actin-bundling protein; in dendritic spines, phosphorylation of isoform-specific sites toggles it between an elongation-competent state and an actin-regulating state, with mGluR signaling triggering its dissociation from its guanine-exchange factor [#11], and disease mutations simultaneously increase tRNA binding while reducing actin bundling [#12]. eEF1A2 also functions as a potent oncogene: it transforms fibroblasts and confers anchorage-independent growth [#2], and it activates PI3K/AKT signaling to promote migration, invasion and MMP-9-dependent metastasis, to stabilize MDM4 and inactivate p53, and to support JAK/STAT-dependent tumor cell survival [#3, #14, #6, #15]. Mechanistically it directly binds and activates PI4KIIIβ to generate PI(4)P [#4, #22], interacts with HSP90β to amplify TGF-β/SMAD3 signaling [#16], sequesters and inhibits the pro-apoptotic kinase PKR [#10], and participates in HIF1A/VEGF angiogenic feedback [#33]. Its abundance and activity are heavily post-translationally controlled — by KAT8-installed K408 lactylation that boosts elongation [#23], by METTL14 m6A and NSUN6 m5C marks on its mRNA [#24, #27], and by ubiquitin-dependent turnover regulated by SNX16 and A20 [#25, #26]. eEF1A2 is the molecular target of the anticancer drug plitidepsin, which binds the domain 1/2 interface in the GTP conformation and releases PKR to trigger apoptosis [#8, #10]. Heterozygous de novo EEF1A2 variants cause neurodevelopmental disease, acting through haploinsufficiency or toxic gain-of-function depending on the allele [#17, #12, #18].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that a tissue-specific elongation factor isoform is non-redundant and essential, reframing translation elongation machinery as developmentally specialized rather than uniform.\",\n      \"evidence\": \"Genetic deletion mapping and Northern blot of the lethal wasted mouse, showing reciprocal eEF1A1/eEF1A2 expression in heart and muscle\",\n      \"pmids\": [\"9539760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular basis of why eEF1A1 cannot substitute\", \"No structural or biochemical distinction between isoforms shown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed that an elongation factor can act as a bona fide oncogene, opening the question of how a translation factor drives transformation.\",\n      \"evidence\": \"Focus formation, anchorage-independent growth, and nude mouse xenografts of eEF1A2-expressing fibroblasts\",\n      \"pmids\": [\"12053177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the signaling effectors mediating transformation\", \"Did not separate translational from non-translational contributions\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified the PI3K/AKT axis and direct PI4KIIIβ activation as the signaling mechanisms underlying eEF1A2 oncogenicity, distinguishing its moonlighting roles from elongation.\",\n      \"evidence\": \"siRNA/overexpression with phospho-Akt blots and inhibitors; in vitro lipid kinase assay with purified recombinant eEF1A2 and cellular PI4P measurement\",\n      \"pmids\": [\"17130842\", \"17088255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which eEF1A2 activates PI3K not resolved\", \"Did not show whether PI4KIIIβ activation and AKT activation are linked\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated isoform-specific protein partnerships, beginning the dissection of why eEF1A2 (not eEF1A1) confers survival advantages.\",\n      \"evidence\": \"Yeast two-hybrid and reciprocal co-IP of eEF1A2 with peroxiredoxin I; cell death and caspase assays; transgenic rescue confirming eEF1A2 loss alone causes wasted phenotype\",\n      \"pmids\": [\"16888816\", \"17640869\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of isoform-specific Prdx-I binding not defined\", \"Prdx-I interaction not linked to elongation activity\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Revealed a non-canonical mRNA-selective translational role, showing eEF1A2 acts as an IRES trans-factor for utrophin A in muscle.\",\n      \"evidence\": \"RNA-affinity chromatography/MS, UV-crosslinking, IRES reporter assays and transgenic mice; parallel shRNA work linking knockdown to JAK/STAT and PI3K/AKT defects\",\n      \"pmids\": [\"20053670\", \"20505761\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sequence/structural determinants of 5'-UTR recognition not mapped\", \"Whether IRES binding uses the tRNA or actin surface unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected eEF1A2 to tumor-suppressor control and downstream proteolytic/metastatic programs, positioning it within established cancer pathways.\",\n      \"evidence\": \"Yeast two-hybrid and domain mapping of p16(INK4a) interaction with translation reporter assays; siRNA/overexpression with MMP-9 zymography and Akt inhibition in pancreatic cancer\",\n      \"pmids\": [\"23444377\", \"23739844\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"p16-eEF1A2 interaction not confirmed by mammalian co-IP\", \"Direct vs indirect control of MMP-9 not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified eEF1A2 as the direct molecular target of plitidepsin, providing both a pharmacological tool and a defined binding site on the protein.\",\n      \"evidence\": \"Binding affinity (KD 80 nM), [14C]-drug pull-down, resistance selection with ectopic rescue, live-cell FLIM-FRET, and molecular modeling of the domain 1/2 interface in GTP conformation\",\n      \"pmids\": [\"27713531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-crystal structure not solved\", \"Whether drug binding blocks elongation or moonlighting functions not separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Explained the apoptotic consequence of plitidepsin by showing eEF1A2 sequesters and inhibits the pro-apoptotic kinase PKR.\",\n      \"evidence\": \"Reciprocal co-IP, HPLC-MS, proximity ligation assay, and plitidepsin displacement experiments linking PKR release to MAPK/NF-κB-driven apoptosis\",\n      \"pmids\": [\"30420615\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and structural basis of PKR sequestration not defined\", \"Single lab; functional consequence shown chemically rather than genetically\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved how a single protein partitions between elongation and actin functions, showing phosphorylation toggles eEF1A2 between the two activities in dendritic spines.\",\n      \"evidence\": \"Phosphomutant/phosphomimetic constructs with translation, actin-dynamics, spine-density, and GEF-interaction readouts under mGluR signaling\",\n      \"pmids\": [\"34257105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The kinase responsible for spine phosphorylation not identified\", \"Identity of the GEF in this context not molecularly defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mechanistically connected patient mutations to disease by showing dual disruption of tRNA availability and actin bundling, distinguishing haploinsufficient from gain-of-function alleles.\",\n      \"evidence\": \"Heterologous expression in HEK293 and cortical neurons with puromycin synthesis, elongation rate, tRNA-binding and actin-bundling assays; prior yeast complementation and zebrafish rescue defining variant effects\",\n      \"pmids\": [\"37695913\", \"32196822\", \"28911200\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How increased tRNA binding mechanistically slows elongation not fully explained\", \"In vivo neuronal phenotypes of specific gain-of-function alleles not modeled\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established post-translational and post-transcriptional regulatory layers controlling eEF1A2 abundance and elongation activity in cancer.\",\n      \"evidence\": \"KAT8-mediated K408 lactylation with translation/tumor assays; METTL14 m6A and NSUN6 m5C mRNA modifications; SNX16 and A20 ubiquitination control; SIMALR lncRNA enhancing GTPase activity\",\n      \"pmids\": [\"38359291\", \"35013140\", \"37614424\", \"31876369\", \"37399716\", \"39154122\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interplay between these regulatory marks not integrated\", \"Several mechanisms shown in single labs without independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How eEF1A2's elongation, IRES-trans-factor, actin-bundling, and signaling activities are coordinated within a single tissue context, and which surface determines each isoform-specific partnership, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of mammalian eEF1A2 with partners\", \"Mechanism switching between elongation and moonlighting functions in vivo unclear\", \"Whether oncogenic signaling depends on elongation activity not definitively separated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [8, 29]},\n      {\"term_id\": \"GO:0045182\", \"supporting_discovery_ids\": [7, 12, 17]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [7, 12, 19]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [11, 12, 19]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [4, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [11, 20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-72766\", \"supporting_discovery_ids\": [12, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 6, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 12, 17]}\n    ],\n    \"complexes\": [\"eEF1B complex (eEF1A2-associated)\"],\n    \"partners\": [\"PI4KB\", \"PRDX1\", \"EIF2AK2\", \"HSP90AB1\", \"CDKN2A\", \"SNX16\", \"TNFAIP3\", \"KAT8\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":6,"faith_total":6,"faith_pct":100.0}}